Biopharmaceutical benchmarks 2006
Top Cited Papers
- 1 July 2006
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (7), 769-776
- https://doi.org/10.1038/nbt0706-769
Abstract
The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.Keywords
This publication has 39 references indexed in Scilit:
- TeGenero fiasco prompts regulatory rethinkNature Biotechnology, 2006
- Biotech drug market steadily expandsNature Biotechnology, 2005
- Making sense of antisenseEuropean Journal Of Cancer, 2005
- Sandoz sues FDA over delay in first biogeneric approvalNature Biotechnology, 2005
- Engineering novel binding proteins from nonimmunoglobulin domainsNature Biotechnology, 2005
- Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of CancersHuman Gene Therapy, 2005
- GENE THERAPY: Twenty-First Century MedicineAnnual Review of Biochemistry, 2005
- Modification of plant N-glycans processing: The future of producing therapeutic protein by transgenic plantsMedicinal Research Reviews, 2005
- The therapeutic antibodies market to 2008European Journal of Pharmaceutics and Biopharmaceutics, 2005
- The humanization of N-glycosylation pathways in yeastNature Reviews Microbiology, 2005